OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$12.15 USD
0.00 (0.00%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $12.11 -0.04 (-0.33%) 4:42 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Earnings News For OPRX
-
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
-
OptimizeRx Reports Third Quarter 2023 Financial Results
-
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
OptimizeRx Reports Second Quarter 2023 Financial Results
-
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
-
OptimizeRx Reports First Quarter 2023 Financial Results
-
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
-
OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results
-
OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET
-
OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth
-
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
-
OptimizeRx Reports Third Quarter 2022 Financial Results
-
OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET
-
OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates
-
OptimizeRx Corp. (OPRX) Reports Next Week: What to Know Ahead of the Release
-
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
-
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
-
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
-
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
-
OptimizeRx Corp. (OPRX) Misses Q3 Earnings Estimates
-
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
-
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
-
OptimizeRx Corp. (OPRX) Q1 Earnings and Revenues Beat Estimates
-
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: Should You Buy?